![]() |
|
NAME
OF THE MEDICAL PRODUCT This drug is used in the treatment of cataracts and has been investigated by Angelini Investigation Institute; it is approved in different countries. The cataract is a degenerative eye disease characterised by the opacification of the crystalline, which may result in vision impairment and subsequent blindness. Its causes may be varied: (senescence, traumas, excess of medicines, exposure to sunlight, diabetes and other dismetabolic diseases, etc), as well as its morphological expressions (capsular cataract, cortical cataract, etc). However, it is presently agreed that in most of the cases the cataract is due to a physical-chemical change in crystalline proteins. Bendaline protects these proteins from any changes and make them more resistant to cataratogenic factors. Studies have demonstrated that this substance penetrates in the crystalline reaching effective concentrations, after sufficiently prolonged treatments. Such concentrations are more rapidly attained by oral route than by topic route. Clinical studies showed that Bendaline is capable of preventing the evolution of several forms of cataracts. The most favourable results were obtained in the initial degenerative forms where it is possible to observe in many cases an improvement in visual acuity, and sometimes, a regression of the crystalline’s opacity. QUALITATIVE
AND QUANTITATIVE COMPOSITION Active substance: Bendazac Lysine Salt ............................................. 500 mg
PHARMACEUTICAL FORM PHARMACOTHERAPEUTIC
CLASS NAME
OR DESIGNATION OF THE RESPONSIBLE FOR THE M.A. THERAPEUTIC
INDICATIONS Bendazac Lysine Salt is also useful in the presence of pre-senile and senile cataract in patients with incipient cataract and in the prevention of secondary cataract (post-surgery opacification of the crystalline and capsules). CONTRAINDICATIONS
AND SIDE EFFECTS DRUG
INTERACTIONS AND OTHER FORMS OF INTERACTION SPECIAL
PRECAUTIONS FOR USE EFFECTS
ON PREGNANT WOMEN, BREAST-FEEDING WOMEN, CHILDREN, ELDERLY PATIENTS AND
PATIENTS WITH SPECIAL PATHOLOGIES No other effects are known in elderly patients and in patients with special pathologies. EFFECTS
ON THE ABILITY TO DRIVE AND USE MACHINES LIST
OF EXCIPIENTS USUAL
POSOLOGY, WITH REFERENCE TO MAXIMUM DOSE INDICATION
OF THE MOST FAVOURABLE MOMENT FOR THE ADMINISTRATION OF THE MEDICINE DURATION
OF THE AVERAGE TREATMENT WHEN IT SHOULD BE LIMITED INDICATION
OF HOW TO DISCONTINUE THE TREATMENT WHEN ITS DISCONTINUATION CAUSES WITHDRAWAL
EFFECTS No special precaution is necessary to suspend the treatment. MEASURES
TO ADOPT IN CASE OF OVERDOSAGE AND/OR INTOXICATION, EMERGENCY SYMPTOMS
AND ANTIDOTES In case of accidental ingestion, it will be useful to perform a stomach lavage, administration of activated carbon and forced diuresis. ADVICE
TO THE PATIENT Check if the product is within the expiry date mentioned in the package. Always keep medicines out of reach and sight of children. SPECIAL
PRECAUTIONS FOR STORAGE AND INDICATION OF VISIBLE SIGNS OF DETERIORATION,
IF THEY EXIST Do not store above 25ºC. DATE OF THE REVISION OF THE LEAFLET: February 2004. |